eflornithine has been researched along with Local Neoplasm Recurrence in 18 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
Excerpt | Relevance | Reference |
---|---|---|
"This study compared the antitumor activity of oral eflornithine with that of oral eflornithine combined with intravenous mitoguazone in the treatment of patients with recurrent or progressive glioblastoma multiforme as well as nonglioblastoma anaplastic gliomas." | 9.07 | Treatment of recurrent gliomas with eflornithine. ( Gleason, MJ; Ictech, S; Levin, VA; Malec, M; Prados, MD; Yung, WK, 1992) |
"The polyamine-inhibitory regimen difluoromethylornithine (DFMO)+sulindac has marked efficacy in preventing metachronous colorectal adenomas." | 7.79 | Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. ( Gerner, EW; McLaren, CE; Meyskens, FL; Raj, KP; Rock, CL; Zell, JA; Zoumas-Morse, C, 2013) |
"A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos." | 5.13 | Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas. ( Chen, WP; Fujikawa-Brooks, S; Gerner, EW; Gillen, DL; McLaren, CE; Meyskens, FL; Pelot, D, 2008) |
"This study compared the antitumor activity of oral eflornithine with that of oral eflornithine combined with intravenous mitoguazone in the treatment of patients with recurrent or progressive glioblastoma multiforme as well as nonglioblastoma anaplastic gliomas." | 5.07 | Treatment of recurrent gliomas with eflornithine. ( Gleason, MJ; Ictech, S; Levin, VA; Malec, M; Prados, MD; Yung, WK, 1992) |
"The polyamine-inhibitory regimen difluoromethylornithine (DFMO)+sulindac has marked efficacy in preventing metachronous colorectal adenomas." | 3.79 | Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. ( Gerner, EW; McLaren, CE; Meyskens, FL; Raj, KP; Rock, CL; Zell, JA; Zoumas-Morse, C, 2013) |
" Experiments were carried out on the trastuzumab-resistant human epidermal growth factor receptor 2-overexpressing breast cancer cell line JIMT-1 to unravel the chemotherapeutic effects of the polyamine analogue [1N,12N]bis(ethyl)-cis-6,7-dehydrospermine (PG11047) and of the polyamine biosynthetic inhibitor 2-difluoromethylornithine (DFMO) on the CD44+CD24- CSC population." | 3.76 | Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047. ( Cirenajwis, H; Hegardt, C; Honeth, G; Marton, LJ; Oredsson, SM; Smiljanic, S, 2010) |
"Two patients died of bladder cancer at 2 and 4 years after randomization, both in the difluoromethylornithine arm." | 2.72 | Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. ( Kim, D; Kim, KM; Messing, E; Parnes, H; Saltzstein, D; Schultz, M; Sharkey, F; Wilding, G, 2006) |
"Patients with resected superficial bladder cancers were studied." | 2.68 | Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. ( Loprinzi, CL; Love, RR; Messing, EM; Morton, RF; Novotny, P; O'Fallon, JR; Poon, MA; Quella, SK; Trump, DL, 1996) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (16.67) | 18.7374 |
1990's | 5 (27.78) | 18.2507 |
2000's | 5 (27.78) | 29.6817 |
2010's | 4 (22.22) | 24.3611 |
2020's | 1 (5.56) | 2.80 |
Authors | Studies |
---|---|
Batth, IS | 1 |
Dao, L | 1 |
Satelli, A | 1 |
Mitra, A | 1 |
Yi, S | 1 |
Noh, H | 1 |
Li, H | 1 |
Brownlee, Z | 1 |
Zhou, S | 1 |
Bond, J | 1 |
Wang, J | 1 |
Gill, J | 1 |
Sholler, GS | 1 |
Li, S | 1 |
Sporn, MB | 1 |
Hong, WK | 1 |
McLaren, CE | 2 |
Fujikawa-Brooks, S | 1 |
Chen, WP | 1 |
Gillen, DL | 1 |
Pelot, D | 1 |
Gerner, EW | 4 |
Meyskens, FL | 2 |
Cirenajwis, H | 1 |
Smiljanic, S | 1 |
Honeth, G | 1 |
Hegardt, C | 1 |
Marton, LJ | 1 |
Oredsson, SM | 1 |
Laukaitis, CM | 1 |
Rial, NS | 1 |
Zell, JA | 2 |
Cohen, AM | 1 |
Raj, KP | 1 |
Rock, CL | 1 |
Zoumas-Morse, C | 1 |
Manni, A | 1 |
Washington, S | 1 |
Craig, L | 1 |
Cloud, M | 1 |
Griffith, JW | 1 |
Verderame, MF | 1 |
Texter, LJ | 1 |
Mauger, D | 1 |
Demers, LM | 1 |
Harms, JF | 1 |
Welch, DR | 1 |
Messing, E | 1 |
Kim, KM | 1 |
Sharkey, F | 1 |
Schultz, M | 1 |
Parnes, H | 1 |
Kim, D | 1 |
Saltzstein, D | 1 |
Wilding, G | 1 |
Tuma, R | 1 |
Loprinzi, CL | 2 |
Messing, EM | 2 |
O'Fallon, JR | 2 |
Poon, MA | 1 |
Love, RR | 1 |
Quella, SK | 1 |
Trump, DL | 1 |
Morton, RF | 1 |
Novotny, P | 1 |
Buckner, JC | 1 |
Burch, PA | 1 |
Cascino, TL | 1 |
Scheithauer, BW | 1 |
Hess, KR | 1 |
Wong, ET | 1 |
Jaeckle, KA | 1 |
Kyritsis, AP | 1 |
Levin, VA | 4 |
Prados, MD | 3 |
Yung, WK | 2 |
Gleason, MJ | 1 |
Ictech, S | 1 |
Malec, M | 1 |
Prados, M | 1 |
Rodriguez, L | 1 |
Chamberlain, M | 1 |
Silver, P | 2 |
Levin, V | 1 |
Chamberlain, MC | 1 |
Choucair, AK | 1 |
Berger, MS | 1 |
Seager, M | 1 |
Gutin, PH | 1 |
Davis, RL | 1 |
Wilson, CB | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase II Preventative Trial of DFMO (Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in Remission[NCT02395666] | Phase 2 | 140 participants (Actual) | Interventional | 2015-03-05 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Pharmacokinetic assay AUC(0-6 hr)/D~Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days" (NCT02395666)
Timeframe: 0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose on two different days
Intervention | hr*ng/mL (Mean) |
---|---|
Study Subjects Consented to PK Collection | 47024 |
To continue to determine the safety and tolerability of DFMO as a single agent and in pediatric and young adult patients with high risk neuroblastoma that is in remission. (NCT02395666)
Timeframe: 2 years
Intervention | Participants (Count of Participants) |
---|---|
DFMO Twice Daily | 57 |
To evaluate the preventative activity of DFMO as a single agent in patients that are in remission based on: Event free survival (EFS) (NCT02395666)
Timeframe: 2 Years
Intervention | percentage of subjects without an event (Mean) |
---|---|
Stratum 1 | 84 |
Stratum 2 | 51 |
"Pharmacokinetic assay Cmax/D~Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days." (NCT02395666)
Timeframe: Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days
Intervention | ng/mL (Mean) |
---|---|
Study Subjects Consented to PK Collection | 11958 |
To evaluate the preventative activity of DFMO as a single agent in patients with neuroblastoma who are in remission based on: Overall Survival (OS) (NCT02395666)
Timeframe: 2 Years
Intervention | percentage of subjects without an event (Mean) |
---|---|
Stratum 1 | 97 |
Stratum 2 | 84 |
"Tests (p-value) of the association of survival with ODC1 single nucleotide polymorphism rs2302616 genotype.~Blood: microRNA analysis as predictor of DFMO effect, ornithine decarboxylase (ODC) single nucleotide polymorphism (SNP) analysis in DNA isolated from nucleated cells" (NCT02395666)
Timeframe: 2 years
Intervention | p-value (Number) |
---|---|
GG, GT, TT | 0.96 |
GG or GT, TT | 0.58 |
GG, GT or TT | 0.67 |
"Pharmacokinetic assay- tmax, hr~Samples drawn at 5 timepoints: (0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose) on two different days" (NCT02395666)
Timeframe: 0 (pre dose), 30min, 1 hour, 3 hours, and 6 hours post-dose on two different days
Intervention | hours (Mean) |
---|---|
Study Subjects Consented to PK Collection | 3.3 |
4 reviews available for eflornithine and Local Neoplasm Recurrence
Article | Year |
---|---|
DFMO: targeted risk reduction therapy for colorectal neoplasia.
Topics: Adenoma; Animals; Anticarcinogenic Agents; Chemoprevention; Colorectal Neoplasms; Eflornithine; Enzy | 2011 |
Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer.
Topics: Adenomatous Polyposis Coli; Antineoplastic Agents; Chemoprevention; Clinical Trials as Topic; Colono | 2012 |
A prospective clinical trial of difluoromethylornithine (DFMO) in patients with resected superficial bladder cancer.
Topics: Clinical Trials as Topic; Eflornithine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; N | 1992 |
Chemotherapy of primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Brain Stem; Child; Efl | 1985 |
6 trials available for eflornithine and Local Neoplasm Recurrence
Article | Year |
---|---|
Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.
Topics: Adenomatous Polyps; Antineoplastic Combined Chemotherapy Protocols; Audiometry, Pure-Tone; Colonic N | 2008 |
Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Double-Blind Method; Eflornithine; Female | 2006 |
Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Chemoprevention; Dose-Response Relationship, Dr | 1996 |
Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma.
Topics: Adult; Aged; Disease Progression; Drug Therapy, Combination; Eflornithine; Female; Glioma; Humans; I | 1998 |
Response and progression in recurrent malignant glioma.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Alitretinoin; Antineoplastic Combine | 1999 |
Treatment of recurrent gliomas with eflornithine.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Child; Child, Preschool; Eflornithine; Female; Glioblastom | 1992 |
8 other studies available for eflornithine and Local Neoplasm Recurrence
Article | Year |
---|---|
Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Early Detection of Cancer; | 2020 |
Clinical prevention of recurrence of colorectal adenomas by the combination of difluoromethylornithine and sulindac: an important milestone.
Topics: Adenoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neopla | 2008 |
Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; | 2010 |
Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Tr | 2013 |
Effects of alpha-difluoromethylornithine on local recurrence and pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice.
Topics: Animals; Eflornithine; Enzyme Inhibitors; Female; Green Fluorescent Proteins; Humans; Luminescent Pr | 2003 |
Drugs to prevent colon cancer show promise, but hurdles remain for chemoprevention.
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Prot | 2008 |
Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1989 |
Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Drug Eval | 1987 |